680596-79-6

Usage

Uses

Used in Organic Synthesis:
1,4-DIOXA-SPIRO[4,5]DEC-7-EN-8-BORONIC ACID, PINACOL ESTER is used as a reagent in organic transformations for its ability to participate in various synthetic reactions, facilitating the construction of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1,4-DIOXA-SPIRO[4,5]DEC-7-EN-8-BORONIC ACID, PINACOL ESTER is utilized as a building block for the synthesis of pharmaceutically relevant compounds, potentially contributing to the development of new drugs.
Used in Material Science:
1,4-DIOXA-SPIRO[4,5]DEC-7-EN-8-BORONIC ACID, PINACOL ESTER is employed in material science for its potential to contribute to the creation of novel materials with specific properties, leveraging its unique structural attributes.
Used in Suzuki-Miyaura Cross-Coupling Reactions:
1,4-DIOXA-SPIRO[4,5]DEC-7-EN-8-BORONIC ACID, PINACOL ESTER is used as a reactant in Suzuki-Miyaura cross-coupling reactions, a significant class of synthetic transformations that are crucial for the formation of carbon-carbon bonds in organic chemistry, particularly valuable in the synthesis of biologically active molecules and advanced materials.

InChI:InChI=1/C14H23BO4/c1-12(2)13(3,4)19-15(18-12)11-5-7-14(8-6-11)16-9-10-17-14/h5H,6-10H2,1-4H3

Upstream product

• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 170011-47-9 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate 
• 73183-34-3 bis(pinacol)diborane 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Downstream Products

• 959939-45-8 benzyl ((4-(1,4-dioxaspiro)[4.5] dec-7-en-8-yl)phenyl)carbamate 
• 1019928-47-2 4-((S)-4-tert-butoxycarbonyl-2-{[6-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-2-phenyl-pyridine-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid ethyl ester 
• 1202389-28-3 8-(2,5-dimethyl-4-nitrophenyl)-1,4-dixoaspiro[4.5]dec-7-ene 
• 1202389-31-8 2-fluoro-5-methyl-4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)aniline 
• 1252615-88-5 [4-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-phenyl]-acetonitrile 
• 1252689-21-6 4-(3-hydroxy-pyridin-2-yl)-cyclohexanone 
• 1352931-41-9 N-(1-(4-(3-hydroxypyridin-2-yl)cyclohexyl)azetidin-3-yl)-2-((6-(trifluoromethyl)quinazolin-4-yl)amino)acetamide 
• 1393685-65-8 8-(2,5-difluoro-4-nitrophenyl)-1,4-dioxa-spiro[4.5]dec-7-ene 
• 1393683-88-9 4-(4-{2,5-difluoro-4-[(3-hydroxy-azetidine-1-carbonyl)amino]phenyl}cyclohexylideneaminooxy)piperidine-1-carboxylic acid tert-butyl ester 
• 1393685-68-1 4-[4-(4-amino-2,5-difluorophenyl)cyclohexylideneaminooxy]piperidin-1-carboxylic acid tert-butyl ester 
• 1393685-92-1 4-[4-(4-amino-2,5-difluorophenyl)cyclohexylideneaminooxy]piperidin-1-carboxylic acid isopropyl ester 
• 1393685-66-9 4-(1,4-dioxa-spiro[4.5]dec-8-yl)-2,5-difluorophenylamine 
• 1407965-47-2 4-(4-amino-2,5-difluoro-phenyl)cyclohexanone O-[1-(4-trifluoromethyl-pyrimidin-2-yl)piperidin-4-yl]oxime 
• 1393686-10-6 4-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-2,5-difluoro-phenylamine 

Relevant academic research and scientific papers

BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS

The present invention is directed to bicyclo[4.1.0]heptane pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Development of a Stereoselective and Scalable Synthesis for the Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, BMT-297376; N-((R)-1-((cis)-4-(3-(Difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide

The current work describes a stereoselective and scalable route to N-((R)-1-((cis)-4-(3-(difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide (1) from readily available 1,4-dioxaspiro[4.5]decan-8-one. The developed process encompasses an efficient 1,4-trans-selective synthesis of (trans)-4-(3-(difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl methanesulfonate as the key intermediate and the use of Ellman sulfinamine methodology to install an alkyl amine in a stereoselective manner. Various synthetic routes were screened to accomplish a stereoselective and scalable protocol to access the title compound (1). This advancement enabled a competent route to the title compound in an enantioselective, safe, cost-effective, and scalable manner.

Arylamine compound, pharmaceutical composition containing arylamine compound as well as preparation method and application of arylamine compound

The present invention relates to an arylamine compound of a formula (I), a pharmaceutical composition comprising the same, a preparation method of the arylamine compound and application of the pharmaceutical composition in the prevention or treatment of diseases or conditions associated with RET activity.

SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR

Disclosed in the present invention are an indoleamine-2,3-dioxygenase inhibitor and a preparation method therefor. The inhibitor of the present invention has a structure as represented by general formula (I), wherein the definitions of Ar, E, Y, X, V, D, W, B, ring A and ring B are as shown in the description and claims. Also disclosed in the present invention is a preparation method for the inhibitor. The compound of general formula (I) of the present invention can be used as an indoleamine-2,3-dioxygenase inhibitor for preparing a medicament for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.

INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND USE OF SAME IN MEDICINE

The present invention relates to a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, a method for inhibiting indoleamine 2,3-dioxygenase, and its use in medicine.

Compound and purpose thereof

The invention provides a novel compound with certain inhibition activity on oxidoreductase indoleamine 2,3-dioxygenase (IDO), or a purpose of the compound for treating related diseases including cancer and immunization-related diseases.

Five-membered heteroaromatic ring derivative, preparation method thereof, pharmaceutical composition and application thereof

The invention discloses a five-membered heteroaromatic ring derivative, a preparation method thereof, a pharmaceutical composition and application thereof. The five-membered heteroaromatic ring derivative (I), isomers, prodrugs, stable isotope derivatives or pharmaceutically acceptable salts thereof have the following structure. The five-membered heteroaromatic ring derivative has a good IDO inhibitory effect, and can effectively treat, relieve and/or prevent various related diseases such as tumors, virus infection or autoimmune diseases, and the like caused by immunosuppression.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

The present invention provides compounds of formula (I), formula (II) or formula (III), wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treat

CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS

The present disclosure describes novel IDO inhibitors and methods for preparing them. The pharmaceutical compositions comprising such IDO inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3 -dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.